Appears on
Articles5
U.S. Study Suggests GLP-1 RA Drugs Are Associated with Small Increase in Ischemic Optic Neuropathy
A target trial emulation found that people with type 2 diabetes who start glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy had a slightly higher risk for ischemic optic neuropathy (ION), a rare condition involving reduced blood flow to the optic nerve that can cause sudden vision loss, compared with those initiating sodium-glucose cotransporter-2 i
Large Swedish Study Suggests Low Overall Risk of Sudden Vision Loss with GLP-1 RA Use
A nationwide cohort study found a slightly higher risk for nonarteritic anterior ischemic optic neuropathy (NAION) among users of glucagon-like peptide-1 receptor agonists (GLP-1RAs) compared with sodium-glucose cotransporter-2 (SGLT-2) inhibitor use.
ACP Says Underregulated Dietary Supplements Endanger Public Health
Dietary supplements must be more regulated to protect public health, says the American College of Physicians (ACP).
One in Three Federally Qualified Health Centers Do Not Offer Direct Prenatal Care
An observational study estimated that 1 in 3 federally qualified health centers (FQHCs) did not offer prenatal care directly in 2024, and many of these clinics were located in maternity care deserts and rural areas.
GLP-1 Initiation Did Not Improve Insulin Discontinuation Rates Among Veterans with Type 2 Diabetes
A target trial emulation found that adding glucagon-like peptide-1 receptor agonists (GLP-1RAs) to basal insulin therapy for type 2 diabetes did not increase the likelihood of stopping insulin therapy compared with adding sodium-glucose cotransporter-2 inhibitor (SGLT-2i) or dipeptidyl peptidase-4 inhibitor (DPP-4i) therapy.